Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Y-mAbs Therapeutics, Inc. - Common Stock (NQ: YMAB )

8.280 -0.290 (-3.38%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Y-mAbs Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMAB
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
ROSEN, A RANKED AND LEADING FIRM, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMAB
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Y-mAbs, Bioventus, ESS, and IBM and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
The Latest Analyst Ratings for Y-mAbs Therapeutics
Via Benzinga
YMAB LOSS ALERT: ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – YMAB
From The Rosen Law Firm PA
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Southwest Airlines, Y-mAbs, Bioventus, and ESS and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
YMAB SHAREHOLDER ALERT: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMAB
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Y-mAbs, Bioventus, ESS, and IBM and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – YMAB
From The Rosen Law Firm PA
Via GlobeNewswire
YMAB SHAREHOLDER ALERT: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Y-mAbs Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - YMAB
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioLineRx, Enovix, Southwest Airlines, and Y-mAbs and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
YMAB LOSS ALERT: ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – YMAB
From The Rosen Law Firm PA
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioLineRx, Enovix, Southwest Airlines, and Y-mAbs and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Y-mAbs Therapeutics, Inc. (YMAB) Investors and Encourages Investors to Contact the Firm Before March 20, 2023
From Kirby McInerney LLP
Via Business Wire
Bronstein, Gewirtz & Grossman, LLC Notifies Y-mAbs Therapeutics, Inc. (YMAB) Investors of Class Action and to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioLineRx, Enovix, Southwest Airlines, and Y-mAbs and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
TOP RANKED ROSEN LAW FIRM Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMAB
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
Y-mAbs Therapeutics, Inc. (YMAB) Investor Alert: Robbins LLP Reminds Shareholders of Class Action Against Y-mAbs Therapeutics, Inc.
From Robbins LLP
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023
Via Benzinga
YMAB NOTICE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMAB
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (YMAB)
From Glancy Prongay & Murray LLP
Via Business Wire
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (YMAB)
From Law Offices of Howard G. Smith
Via Business Wire
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate. 
Via MarketBeat
Topics Workforce
Exposures Layoff Product Safety
Y-MABS THERAPEUTICS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess Of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. - YMAB
From Kahn Swick & Foti, LLC
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Y-mAbs Therapeutics, Inc. (YMAB) Investors
From Glancy Prongay & Murray LLP
Via Business Wire
NOTICE: Investors in Y-mAbs Therapeutics, Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – YMAB
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioLineRx, Enovix, Southwest Airlines, and Y-mAbs and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Y-mAbs Therapeutics (YMAB) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Y-mAbs Therapeutics, Inc. (YMAB) Investors
From Law Offices of Howard G. Smith
Via Business Wire
ROSEN, A TOP RANKED LAW FIRM, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMAB
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.